NEUROPSYCHOPHARMACOLOGY is a prestigious academic journal dedicated to advancing our understanding of the intricate relationship between psychiatric disorders and pharmacological treatments. Published by SpringerNature in the United Kingdom, this leading journal has been a cornerstone in the field since its inception in 1987, with a converged publication timeline extending to 2024. With a remarkable impact factor and illustrious rankings—being positioned 19th in Psychiatry and Mental Health and 16th in Pharmacology—NEUROPSYCHOPHARMACOLOGY is recognized for its rigorous peer-reviewed research that informs clinical practice and enhances therapeutic interventions. The journal is classified in Q1 quartile categories for both Pharmacology and Psychiatry and Mental Health, highlighting its commitment to excellence. Researchers, professionals, and students are encouraged to contribute to this vital dialogue, as the journal does not currently offer open access, emphasizing the importance of curated, high-quality content. By publishing innovative studies and reviews, NEUROPSYCHOPHARMACOLOGY plays a crucial role in shaping the future of mental health treatments and understanding neurobiological mechanisms, making it an indispensable resource for those at the forefront of psychiatric research.

Progress in Neurology and Psychiatry is a pivotal journal published by John Wiley & Sons Ltd, dedicated to advancing the fields of neurology and psychiatry. With a robust history dating back to its establishment, this esteemed journal holds a consistent Q3 ranking in 2023 across several categories including Neurology, Clinical Neurology, Psychiatry, and Mental Health, signifying its significant contribution to the scientific community. This journal serves as a vital source of knowledge and insight, publishing original research, reviews, and case studies that explore the intricacies of neurological and psychiatric disorders. Although it does not offer open access, the journal remains accessible to a wide audience through institutional subscriptions. By fostering a platform for scholarly discourse, Progress in Neurology and Psychiatry aims to bridge the gap between research and practice, ultimately enhancing the quality of care for individuals with neurological and psychiatric conditions. Researchers, clinicians, and students are encouraged to engage with the journal's comprehensive content to stay informed of the latest developments and emerging trends in these critical fields of medicine.

European Archives of Psychiatry and Clinical Neuroscience is a prominent peer-reviewed journal published by Springer Heidelberg, focusing on the interdisciplinary aspects of psychiatry and clinical neuroscience. With an ISSN of 0940-1334 and an E-ISSN of 1433-8491, this journal provides a rigorous platform for innovative research spanning biological psychiatry, pharmacology, and various aspects of mental health. The journal boasts a distinguished impact factor that places it in the Q2 category for Biological Psychiatry and Q1 in both Medicine (miscellaneous) and Psychiatry and Mental Health as of 2023, reflecting its significant contribution to the field. Additionally, its Scopus rankings highlight its esteemed position among the top journals, particularly in Medicine and Neuroscience disciplines. Readers can access a wealth of valuable research articles, case studies, and reviews, crucial for advancing understanding and treatment within these vital fields. Initially converged in 1990, the journal continues to evolve and support scholarly dialogue until 2024 and beyond, making it an essential resource for researchers, clinicians, and students alike.

FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE is a pivotal journal in the fields of neurology, psychiatry, and related medical disciplines, published by GEORG THIEME VERLAG KG in Germany. With a history dating back to 1955, this journal has evolved to address the dynamic nature of neurological and psychiatric research, offering valuable insights and advancements in the field. Despite holding a Q4 category status in various medical domains according to the 2023 quartiles, the journal continues to foster academic discussion and engagement among researchers and clinicians alike. It serves as a vital platform for disseminating knowledge through original research articles, reviews, and clinical studies, making it an essential resource for professionals and students aiming to stay abreast of the latest developments in mental health and neurological science. Although the journal currently does not offer open access options, its contribution to the academic community is significant, helping to illuminate the intricate relationships between neurological disorders and psychiatric conditions.

JPAD - Journal of Prevention of Alzheimer’s Disease, published by Springer Basel AG, is a premier academic journal dedicated to advancing research in the critical field of Alzheimer’s disease prevention. Its impactful contributions to the fields of neurology, psychiatry, and mental health have led it to achieve a Q1 ranking in multiple categories, including neurology (clinical) and psychiatry and mental health. Since its inception in 2017, JPAD has become an essential platform for researchers and professionals aiming to stay at the forefront of developments in Alzheimer’s disease research, prevention strategies, and innovative therapies. The journal provides a valuable open access option for disseminating high-quality research to a global audience, enhancing its visibility and impact. With its strategic focus and rigorous peer-review process, JPAD is committed to fostering collaboration and knowledge exchange among scientists, clinicians, and practitioners, ultimately contributing to the global effort to combat Alzheimer's disease.

Schizophrenia Research and Treatment, an esteemed journal published by HINDAWI LTD, serves as a pivotal open-access platform for innovative research in the fields of Neurology and Psychiatry. With an ISSN of 2090-2085 and E-ISSN of 2090-2093, this journal has established itself as a significant resource for scholars and practitioners since its inception in 2011, consistently contributing to the understanding and treatment of schizophrenia and related mental health issues. Based in Egypt and reaching a global audience, Schizophrenia Research and Treatment is classified in the 2023 Q2 category for both Neurology (Clinical) and Psychiatry and Mental Health, reflecting its importance and relevance in these disciplines. Notably, the journal ranks in the 61st percentile for Psychiatry and Mental Health and the 58th percentile for Clinical Neurology, indicating its solid reputation among peers. By disseminating critical findings and fostering dialogue among researchers, professionals, and students, this journal plays a crucial role in advancing the treatment and management of schizophrenia, ultimately benefiting patients and healthcare systems worldwide.

Journal of Eating Disorders, published by BMC, is a leading Open Access journal dedicated to advancing knowledge and understanding of eating disorders. With an ISSN of 2050-2974, it has been a valuable resource for researchers and practitioners since its inception in 2013. This journal resides in the prestigious United Kingdom and provides a platform for high-quality research, encompassing areas such as behavioral neuroscience, nutrition and dietetics, as well as psychiatry and mental health. Notably, it achieved an impressive Q1 ranking in Nutrition and Dietetics and holds a Q2 classification in both Behavioral Neuroscience and Psychiatry and Mental Health for the year 2023. With a robust Scopus ranking, including a 67th percentile in Psychiatry and Mental Health, the journal is committed to facilitating vital discourse and disseminating groundbreaking findings that cater to both academic and clinical settings. The wide-reaching impact of the research published within its pages makes it an essential tool for professionals, students, and anyone with an interest in understanding and addressing eating disorders.

ACTA NEUROPSYCHIATRICA is a distinguished journal published by Cambridge University Press, covering essential research across the fields of psychiatry and neuroscience. Since its inception in 1989, it has become a pivotal resource for researchers and clinicians, providing a platform for the latest advancements and insights in biological psychiatry. With an impressive Scopus rank of #66 out of 567 in the Psychiatry and Mental Health category, and #10 out of 51 in Biological Psychiatry, the journal is recognized for its significant contributions to the field, boasting an 88th percentile ranking in overall impact. Although it operates under a traditional access model, the journal remains committed to disseminating high-quality research that addresses critical issues in mental health. Whether you are a professional seeking the latest findings or a student aiming to deepen your knowledge, ACTA NEUROPSYCHIATRICA is an indispensable resource for cutting-edge developments that shape our understanding of the human mind.

Journal of Psychiatric Practice, published by Lippincott Williams & Wilkins, is a premier journal dedicated to advancing the field of psychiatry and mental health. With a focus on evidence-based clinical practice, the journal has been a respected resource since its inception, providing a platform for a wide range of articles, including original research, reviews, and case reports from 1997 to the present. As of 2023, it holds a Q3 ranking in Psychiatry and Mental Health, reflecting its influential role in the academic community. The Journal is aimed at researchers, mental health professionals, and students, promoting the dissemination of essential knowledge and innovative practices. Subscribers benefit from the latest findings and discussions in the field while contributing to the ongoing advancements in psychiatric care. Although not classified as open access, the journal ensures wide accessibility to its valuable content, further solidifying its commitment to the mental health discipline.

Schizophrenia Research is a premier academic journal focused on innovative research within the domain of psychiatry and mental health, published by Elsevier. With its ISSN 0920-9964 and E-ISSN 1573-2509, the journal has established a strong presence since its inception in 1988, evolving to publish cutting-edge findings up to 2024. Positioned in Q1 in Psychiatry and Mental Health and Q2 in Biological Psychiatry, it ranks impressively in the 83rd percentile among its peers, according to Scopus, ranking #93/567 in the field of Medicine, and #12/51 in Neuroscience. This journal serves as a vital platform for the dissemination of significant scientific advancements and theoretical insights into schizophrenia, fostering a deeper understanding of mental illnesses. Although it operates on a subscription basis, its critical role in informing both ongoing research and clinical practices cannot be overstated, making it an essential resource for researchers, clinicians, and students alike. Join a global community dedicated to improving mental health outcomes and advancing the study of schizophrenia through this reputable publication.